Good time to highlight my impeccable flight etiquette:→ I have snacks (protein bars, water, edamame)→ Tech kit for emergency charges, cables, headphones→ I won't have to piss, but I will get up and stretch around hour 5. Just some calf raises and toe touches.→ I will neatly eat and throw away my in-flight meal (I'll also wake you for yours if requested)→ I only take up one seat→ I tip all flight attendants 20% of flight, as is commiserate of a US-based serviceBonus:If you want extra airline snacks I know ho ...

Core Insights - Samuel Adams has renewed its multiyear partnership with the Boston Red Sox, remaining the team's Official Beer for the next decade, which began in 2018 [1][3] - The partnership will also include other Boston Beer brands such as Angry Orchard, Truly, and Twisted Tea [1] - The collaboration emphasizes the deep roots of both brands in Boston and their commitment to enhancing the fan experience at Fenway Park [3] Company Overview - Samuel Adams is a leading independent American craft brewer, founded in 1984, known for its flagship Boston Lager and its role in the craft beer revolution [6][7] - The Boston Beer Company, which owns Samuel Adams, has expanded its portfolio to include hard cider, hard seltzer, and hard tea, with a focus on innovation and quality [8] - The company has a philanthropic program called Brewing the American Dream, aimed at supporting entrepreneurs and fellow brewers [6] Partnership Details - The Sam Deck in right field at Fenway Park remains a popular destination for fans, with over 275,000 pints of Sam Adams served [2] - The partnership will feature special events, including watch parties at the Downtown Boston Taproom and Boston Brewery, and the introduction of a new beer, Grand Slam Adams, for the Sox season [3][4] - Samuel Adams has a history of community involvement, including being the official beer of the Boston Marathon and supporting local charities [4]

Exploring Strategic Partnerships to Expand Platform Beyond Reproductive HealthSAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced the receipt of a $6 million non-dilutive funding installment under its multi-year grant agreement to support development of DARE-LARC1, the contraception-focused use case of Daré’s intelligent drug delivery system (DARE-IDDS ...

New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the Complete Response Letter (CRL) for CARDAMYST™ (etripamil) nasal spray, an investigational, novel therapy for the treatment of patients ...

MILWAUKEE, WI, July 09, 2025 (GLOBE NEWSWIRE) -- WEYCO Group, Inc. (NASDAQ: WEYS), a global marketer of footwear, plans to announce second quarter 2025 financial results after the close on Tuesday, August 5, 2025. Additionally, Thomas W. Florsheim, Jr., Chairman and CEO, will host a conference call on Wednesday, August 6, 2025, at 11:00 a.m. Eastern Time to discuss the financial results in more detail. To participate in the call, you will first need to pre-register online. Pre-registration takes only a few ...

Milestone Pharmaceuticals Inc. (NASDAQ: MIST ) is a microcap biotech company that was founded in 2003. It is based in Montreal, but also has a subsidiary in Charlotte, NC, with 30+ employees split fairly evenly between the two locations. Milestone IPO’d inI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greate ...

Key Highlights of SpringWorks Therapeutics - OGSIVEO (nirogacestat) is the first and only FDA-approved therapy for desmoid tumors[15] - GOMEKLI (mirdametinib) is the first and only FDA-approved therapy for both adults and children with NF1-PN[15] - SpringWorks Therapeutics expects profitability in the first half of 2026[10] - SpringWorks Therapeutics had $461.9 million in cash, cash equivalents, and marketable securities[132] OGSIVEO (Nirogacestat) for Desmoid Tumors - OGSIVEO generated $61.5 million in net revenue in Q4 2024 and $172.0 million in FY 2024[15] - Between October 2023 and October 2024, approximately 11,000 patients with desmoid tumor ICD-10 claims were identified[15] - Objective response rate (ORR) increased from 34.3% with up to 1 year of treatment to 45.7% with up to 4 years of treatment[48] GOMEKLI (Mirdametinib) for NF1-PN - GOMEKLI is approved for the treatment of adult and pediatric patients 2 years of age and older with NF1-PN[10] - The U S market includes approximately 30,000 adult and 10,000 pediatric patients with NF1-PN[15] - In clinical trials, GOMEKLI showed a confirmed overall response rate of 41% in adults (n=58) and 52% in pediatrics (n=56)[67]

The July 4 departure aboard Zuiderdam sails roundtrip from Boston and includes an overnight in New York and a visit to Norfolk, VirginiaSEATTLE, July 3, 2025 /PRNewswire/ -- In honor of America's 250th birthday in 2026, Holland America Line is sailing a landmark cruise roundtrip from Boston — the epicenter of the American Revolution. The seven-day "America's 250th Celebration: Stars & Stripes Voyage" aboard Zuiderdam departs July 4, 2026, and includes a visit to Saint John, New Brunswick, Canada, an overnig ...

June 9, 2025 1 NASDAQ: DARE www.darebioscience.com ©2025 Daré Bioscience | All rights reserved 1 TRANSFORMING WOMEN'S HEALTH We founded Daré with the sole focus of putting women's health first – to boldly address existing gaps and give women the treatment options they want and deserve In Italian, it means "TO GIVE" DARE: In English, it means "TO BE BOLD" 2 2 Forward-Looking Statements; Disclaimers This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer ...

Company Overview - Boston Beer (SAM) shares increased by 4.6% to $199.64 in the last trading session, following a period of 13.6% loss over the past four weeks, indicating a significant recovery in stock performance [1] - The company is experiencing benefits from brand strength, effective price realization, and procurement savings, which are mitigating the effects of inflationary costs [2] Financial Performance - Boston Beer is projected to report quarterly earnings of $4.40 per share, reflecting a year-over-year increase of 0.2%, with expected revenues of $598.55 million, up 3.4% from the same quarter last year [3] - The consensus EPS estimate for Boston Beer has remained stable over the last 30 days, suggesting that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Boston Beer is part of the Zacks Beverages - Alcohol industry, where another company, Molson Coors Brewing (TAP), saw a 2% increase in its stock price to $49.07, but has returned -9% over the past month [5] - Molson Coors has a consensus EPS estimate of $1.89, which has decreased by 0.7% over the past month, indicating a decline of 1.6% compared to the previous year [6]